In this issue:
SMBG in non-insulin-treated type 2 diabetes in primary care
CV and metabolic effects of metformin in type 1 diabetes
Combining fasiglifam with sitagliptin in type 2 diabetes
Atherosclerosis after intensive intervention in type 2 diabetes
Low urinary pH predicts diabetes in men
Examining biomarkers associated with heart disease
Plasma glucose response to exercise in adolescents with type 1 diabetes
Dapagliflozin + exenatide in non-diabetic obese adults
SGLT2 inhibitors lower CVD risk in type 2 diabetes
Insights into benefits and adverse effects of metformin
Please login below to download this issue (PDF)